Very early researchStudy completedNCT03763643
What this trial is testing
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
Who this might be right for
Focal Segmental Glomerulosclerosis
University of Minnesota 21